A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

BACKGROUND Clinical trials have indicated a benefit of adjuvant chemotherapy for patients with stage IB, II, or IIIA--but not stage IA--non-small-cell lung cancer (NSCLC). This classification scheme is probably an imprecise predictor of the prognosis of an individual patient. Indeed, approximately 25 percent of patients with stage IA disease have a recurrence after surgery, suggesting the need to identify patients in this subgroup for more effective therapy. METHODS We identified gene-expression profiles that predicted the risk of recurrence in a cohort of 89 patients with early-stage NSCLC (the lung metagene model). We evaluated the predictor in two independent groups of 25 patients from the American College of Surgeons Oncology Group (ACOSOG) Z0030 study and 84 patients from the Cancer and Leukemia Group B (CALGB) 9761 study. RESULTS The lung metagene model predicted recurrence for individual patients significantly better than did clinical prognostic factors and was consistent across all early stages of NSCLC. Applied to the cohorts from the ACOSOG Z0030 trial and the CALGB 9761 trial, the lung metagene model had an overall predictive accuracy of 72 percent and 79 percent, respectively. The predictor also identified a subgroup of patients with stage IA disease who were at high risk for recurrence and who might be best treated by adjuvant chemotherapy. CONCLUSIONS The lung metagene model provides a potential mechanism to refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions regarding the use of adjuvant chemotherapy in early-stage NSCLC.

[1]  L. Leslie,et al.  A decade of progress. , 1969, Minnesota medicine.

[2]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[3]  C. Mountain.  The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.

[4]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[5]  J. Roth,et al.  Survival in early-stage non-small cell lung cancer. , 1995, The Annals of thoracic surgery.

[6]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[7]  Adrian F. M. Smith,et al.  A Bayesian CART algorithm , 1998 .

[8]  D. Harpole,et al.  A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. , 1999, The Journal of thoracic and cardiovascular surgery.

[9]  O. Stoeltzing,et al.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer , 2000, British Journal of Cancer.

[10]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Leo Breiman,et al.  Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author) , 2001 .

[14]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Leo Breiman,et al.  Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author) , 2001, Statistical Science.

[16]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[17]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[18]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[19]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[20]  Yusuke Nakamura,et al.  Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.

[21]  Holly Dressman,et al.  Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. , 2003, Human molecular genetics.

[22]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Ettinger,et al.  Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.

[24]  R. Schilsky,et al.  Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. West,et al.  Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[27]  Mike West,et al.  Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. , 2004, Biostatistics.

[28]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[29]  R. Rosell,et al.  ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association , 2005 .

[30]  R. Lotan,et al.  Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells , 2005, Molecular Genetics and Genomics.

[31]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[32]  L. Chin,et al.  High-resolution genomic profiles of human lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Werner Dubitzky,et al.  Survival Trees for Analyzing Clinical Outcome in Lung Adenocarcinomas Based on Gene Expression Profiles: Identification of Neogenin and Diacylglycerol Kinase Expression as Critical Factors , 2005, J. Comput. Biol..

[34]  Michael L. Wang,et al.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Meyerson,et al.  Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.